SBI-425 is an inhibitor of tissue-nonspecific alkaline phosphatase (TNAP; IC50 = 0.016 ?M).1 It is selective for TNAP over a panel of 35 targets at 10 ?M. SB-425 (10 and 30 mg/kg) increases survival and nearly completely inhibits the development of medial arterial calcification in a mouse model of chronic kidney disease-mineral bone disorder (CKD-MBD) induced by a high-adenine high-phosphate diet.2
1.Pinkerton, A.B., Sergienko, E., Bravo, Y., et al.Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitorBioorg. Med. Chem. Lett.28(1)31-34(2018) 2.Tani, T., Fujiwara, M., Orimo, H., et al.Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse modelJ. Pathol.250(1)30-41(2020)